Martin Auster
Stock Analyst at UBS
(2.22)
# 2,509
Out of 4,820 analysts
47
Total ratings
51.61%
Success rate
4.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $62.98 | +90.54% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $37.98 | +176.46% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $3.57 | +628.29% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $3.26 | +3,586.64% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $2.65 | +11,220.75% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $9.49 | +511.49% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $297.04 | -34.02% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $0.54 | +18,214.33% | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | $50 → $60 | $69.86 | -14.11% | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $65 | $31.71 | +104.98% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $61.51 | +18.68% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $3.47 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $13.97 | +458.34% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.91 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $6.51 | +561.03% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $31.21 | +8.94% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $8.48 | +147.64% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $21.28 | -24.81% | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $62.98
Upside: +90.54%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $37.98
Upside: +176.46%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $3.57
Upside: +628.29%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $3.26
Upside: +3,586.64%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $2.65
Upside: +11,220.75%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $9.49
Upside: +511.49%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $297.04
Upside: -34.02%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $0.54
Upside: +18,214.33%
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $69.86
Upside: -14.11%
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $31.71
Upside: +104.98%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $61.51
Upside: +18.68%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $3.47
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $13.97
Upside: +458.34%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $0.91
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $6.51
Upside: +561.03%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $31.21
Upside: +8.94%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $8.48
Upside: +147.64%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $21.28
Upside: -24.81%